2024
1) Vertical mother‐to‐infant transmission of herpes simplexvirus 2 is correlated with tropism due to mutations in viral UL13
Kimiyasu Shiraki, Tohru Daikoku, Mark N. Prichard, Koma Matsuo,
Tomoko Okuda, Yoshihiro Yoshida, Masaya Takemoto, Kenji Takeuchi, Kiyonao Sada, Richard Whitley, Takashi Kawana
J. Med. Virol. 2024 Jan 18;96(1):e29379. https://onlinelibrary.wiley.com/doi/10.1002/jmv.29379
2) Mortality risk factors and fulminant sub-phenotype in anaerobic bacteremia: a 10-year retrospective, multicenter, observational cohort study
Kentaro Nagaoka, N Iwanaga, Y Takegoshi, Y Murai, H Kawasuji, M Miura, Y Sato, Y Hatakeyama, H Ito, Y Kato, N Shibayama, Y Terasaki, T Fujimura, T Takazono, K Kosai, A Sugano, Y Morinaga, K Yanagihara, H Mukae, Y Yamamoto
Eur J Clin Microbiol Infect Dis.2024 Mar;43(3):459-467.https://link.springer.com/article/10.1007/s10096-023-04743-1
3) Impact of COVID-19 and Closed Transmission of SARS-CoV-2 during the First Wave in Toyama Prefecture, Japan, March 30 to May 18, 2020
Tamura K, Inasaki N, Itamochi M, Saga Y, Shimada T, Yazawa S, Sasajima H, Kawashiri C, Yamazaki E, Ichikawa T, Kaya H, Yamamoto Y, Morinaga Y, Yamashiro S, Nomura S, Takeda S, Ito H, Hirota K, Horie Y, Hirano N, Sekizuka T, Kuroda M, Tani H, Oishi K.
Jpn J Infect Dis. 2024 Mar 21;77(2):75-82. https://doi.org/10.7883/yoken.JJID.2023.210
4) Identification of herbal drug extracts that promote growth of Akkermansia muciniphila in high-fat diet fed mice
Shiho Fujisaka, Yoshiyuki Watanabe, Kazufumi Toume, Yoshitomo Morinaga, Allah Nawaz, Tomonobu Kado, Ayumi Nishimura, Muhammad Bilal, Muhammad Rahil Aslam, Yoshiko Igarashi, Yoshimi Nakagawa, Kazuyuki Tobe
Diabetol Int.2024 Apr 6;15(3):495-506.https://link.springer.com/article/10.1007/s13340-024-00713-w
8) High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection. Kawasuji H, Morinaga Y, Nagaoka K, Tani H, Yoshida Y, Yamada H, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Niimi H, Yamamoto Y. Front Immunol. 2024 15:1377014. https://doi.org/10.3389/fimmu.2024.1377014
3) Potent immunogenicity and neutralization of recombinant adeno-associated virus expressing the glycoprotein of severe fever with thrombocytopenia virus. Shimoyama T, Oba M, Takemae H, Omatsu T, Tani H, Mizutani T. J Vet Med Sci. 2024 Feb 15;86(2):228-238. https://doi.org/10.1292/jvms.23-0375
4) Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1. Ozawa T, Ikeda Y, Chen L, Suzuki R, Hoshino A, Noguchi A, Kita S, Anraku Y, Igarashi E, Saga Y, Inasaki N, Taminishi S, Sasaki J, Kirita Y, Fukuhara H, Maenaka K, Hashiguchi T, Fukuhara T, Hirabayashi K, Tani H, Kishi H, Niimi H. Structure. 2024 Mar 7;32(3):263-272.e267. https://doi.org/10.1016/j.str.2023.12.013
5) Characterization of antibodies targeting severe fever with thrombocytopenia syndrome virus glycoprotein Gc. Sano K, Kimura M, Sataka A, Hasegawa H, Tani H, Suzuki T. Arch Virol. 2024 Feb 3;169(3):40. https://doi.org/10.1007/s00705-024-05968-x
6) Evaluation of MALDI-TOF mass spectrometry coupled with ClinProTools as a rapid tool for toxin-producing Clostridioides difficile. Nakayama A, Morinaga Y, Izuno R, Morikane K, Yanagihara K. J Infect Chemother. 2024 Feb 28. https://doi.org/10.1016/j.jiac.2024.02.024
7) Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne. Murae M, Sakai S, Miyata N, Shimizu Y, Okemoto-Nakamura Y, Kishimoto T, Ogawa M, Tani H, Tanaka K, Noguchi K, Fukasawa M. Biol Pharm Bull. 2024 47(5):930-940. https://doi.org/10.1248/bpb.b23-00797
2) Pathological and virological findings of type I interferon receptor knockout mice upon experimental infection with Heartland virus. Fujii H, Fukushi S, Yoshikawa T, Nagata N, Taniguchi S, Shimojima M, Yamada S, Tani H, Uda A, Maeki T, Harada S, Kurosu T, Lim C K, Nakayama E, Takayama-Ito M, Watanabe S, Ebihara H, Morikawa S, Saijo M. Virus Res. 2024 Feb;340:199301. https://doi.org/10.1016/j.virusres.2023.199301
9) Onnamide A suppresses the severe acute respiratory syndrome-coronavirus 2 infection without inhibiting 3-chymotrypsin-like cysteine protease. Hayashi Y, Higa N, Yoshida T, Tyas T A, Mori-Yasumoto K, Yasumoto-Hirose M, Tani H, Tanaka J, Jomori T. J Biochem. 2024 Sep 3;176(3):197-203. https://doi.org/10.1093/jb/mvae037
10) Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots. Kawasuji H, Morinaga Y, Tani H, Yamada H, Yoshida Y, Ezaki M, Koshiyama Y, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Nagaoka K, Niimi H, Yamamoto Y. Vaccine. 2024 Sep 17;42(22):126029. https://doi.org/10.1016/j.vaccine.2024.05.077
11) Characteristics of virus and antibody response in an immunocompromised patient with persistent SARS-CoV-2 infection. Yazawa S, Fukuyama K, Kawakami R, Itamochi M, Higashi D, Tsuji N, Nakamura M, Oishi K, Kaya H, Tani H. J Infect Chemother. 2024 Aug 30. https://doi.org/10.1016/j.jiac.2024.08.024
12) Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles. Omata D, Kawahara E, Munakata L, Tanaka H, Akita H, Yoshioka Y, Suzuki R. Mol Pharm. 2024 Nov 4;21(11):5672-5680. https://doi.org/10.1021/acs.molpharmaceut.4c00628
13) COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naïve nursing home residents. Itamochi M, Yazawa S, Saga Y, Shimada T, Tamura K, Maenishi E, Isobe J, Sasajima H, Kawashiri C, Tani H, Oishi K. Sci Rep. 2024 Oct 7;14(1):23295. https://doi.org/10.1038/s41598-024-73004-8
14) Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction. Kawahara E, Senpuku K, Kawaguchi Y, Yamamoto S, Yasuda K, Kuroda E, Ouji-Sageshima N, Ito T, Hirai T, Shibata T, Yoshioka Y. NPJ Vaccines. 2024 Oct 12;9(1):187. https://doi.org/10.1038/s41541-024-00987-w
15) Association between sore throat and early immune responses against COVID-19 before and after the emergence of the Omicron variant. Takegoshi Y, Nagaoka K, Kido T, Kawasuji H, Murai Y, Kaneda M, Kimoto K, Tani H, Niimi H, Morinaga Y, Yamamoto Y. Ann Transl Med. 2024 Oct 20;12(5):87. https://doi.org/10.21037/atm-24-36
16) Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Kawai A, Shimizu T, Tanaka H, Shichinohe S, Anindita J, Hirose M, Kawahara E, Senpuku K, Shimooka M, Quynh Mai L T, Suzuki R, Nogimori T, Yamamoto T, Hirai T, Kato T, Watanabe T, Akita H, Yoshioka Y. Mol Ther. 2024 Dec 17. https://doi.org/10.1016/j.ymthe.2024.12.032
NEWS
渡辺彩愛さん（医学部医学科4年）が第94回日本感染症学会西日本地方会学術集会・第72回日本化学療法学会西日本支部総会にて優秀賞（口頭）を受賞しました / Watanabe A, 2024 Nov 16
2023
1) Analytical sensitivity of six lateral flow antigen test kits for variant strains of SARS-CoV-2. Morinaga Y, Yamada H, Yoshida Y, Kawasuji H, Yamamoto Y.
J Infect Chemother. 2023 Feb;29(2):131-135. https://doi.org/10.1016/j.jiac.2022.10.00
2) Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
Kawasuji H, Morinaga Y, Tani H, Saga Y, Yamada H, Yoshida Y, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Ueno A, Miyajima Y, Nagaoka K, Ono C, Matsuura Y, Niimi H, Yamamoto Y.
Microbiol Spectr. 2023 Mar 22;11(2):e0513122. https://doi.org/10.1128/spectrum.05131-22
3) Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants.
Nagaoka K, Kawasuji H, Takegoshi Y, Murai Y, Kaneda M, Kimoto K, Tani H, Niimi H, Morinaga Y, Noguchi K, Yamamoto Y.
Viruses. 2023 May 31;15(6). https://doi.org/10.3390/v15061304
4) The fecal carriage rate of extended-spectrum β-lactamase-producing or carbapenem-resistant Enterobacterales among Japanese infants in the community at the 4-month health examination in a rural city.
Kawata S, Morimoto S, Kosai K, Kawamoto Y, Nakashima Y, Morinaga Y, Yanagihara K, Yoshida L M, Moriuchi H.
Front Cell Infect Microbiol. 2023 13:1168451. https://doi.org/10.3389/fcimb.2023.1168451
5) Association of subpleural ground-glass opacities with respiratory failure and RNAemia in COVID-19.
Nagaoka K, Kawasuji H, Takegoshi Y, Murai Y, Kaneda M, Ueno A, Miyajima Y, Wakasugi M, Noguchi K, Morimoto S, Morinaga Y, Yamamoto Y.
European Radiology. 2023 33(7):4713-4722. https://doi.org/10.1007/s00330-023-09427-0
6) Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19.
Yamazaki E, Yazawa S, Shimada T, Tamura K, Saga Y, Itamochi M, Inasaki N, Hasegawa S, Morinaga Y, Oishi K, Tani H.
Sci Rep. 2023 Jul 19;13(1):11632. https://doi.org/10.1038/s41598-023-38757-8
7) Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2019-2020: General view of the pathogens' antibacterial susceptibility.
Tokimatsu I, Matsumoto T, Tsukada H, Fujikura Y, Miki M, Morinaga Y, Sato J, Wakamura T, Kiyota H, Tateda K, Yanagisawa H, Sasaki T, Ikeda H, Horikawa H, Takahashi H, Seki M, Mori Y, Takeda H, Kurai D, Hasegawa N, Uwamino Y, Kudo M, Yamamoto M, Nagano Y, Nomura S, Tetsuka T, Hosokai M, Aoki N, Yamamoto Y, Iinuma Y, Mikamo H, Suematsu H, Maruyama T, Kawabata A, Sugaki Y, Nakamura A, Fujikawa Y, Fukumori T, Ukimura A, Kakeya H, Niki M, Yoshida K, Kobashi Y, Tokuyasu H, Yatera K, Ikegami H, Fujita M, Matsumoto T, Yanagihara K, Matsuda J, Hiramatsu K, Shinzato T.
J Infect Chemother. 2023 Aug;29(8):731-743. https://doi.org/10.1016/j.jiac.2023.04.008
8) Predictive values of immune indicators on respiratory failure in the early phase of COVID-19 due to Delta and precedent variants.
Nagaoka K, Kawasuji H, Takegoshi Y, Murai Y, Kaneda M, Kimoto K, Morimoto S, Tani H, Niimi H, Morinaga Y, Yamamoto Y.
Frontiers in Immunology. 2023 Sep:14. https://doi.org/10.3389/fimmu.2023.1197436
９) The clinical characteristics and molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) among very elderly people in Japan.
Mitsumoto-Kaseida F, Morinaga Y, Sasaki D, Ota K, Kaku N, Sakamoto K, Kosai K, Hasegawa H, Hayashi J, Yanagihara K.
Geriatr Gerontol Int. 2023 Oct;23(10):744-749. https://doi.org/10.1111/ggi.14664
10) High Incidence of Metastatic Infections in Panton-Valentine Leucocidin-Negative, Community-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia: An 11-Year Retrospective Study in Japan.
Kawasuji H, Ikezawa Y, Morita M, Sugie K, Somekawa M, Ezaki M, Koshiyama Y, Takegoshi Y, Murai Y, Kaneda M, Kimoto K, Nagaoka K, Niimi H, Morinaga Y, Yamamoto Y.
Antibiotics (Basel). 2023 Oct 6;12(10). https://doi.org/10.3390/antibiotics12101516
11) A high α1-antitrypsin/interleukin-10 ratio predicts bacterial pneumonia in adults with community-acquired pneumonia: a prospective cohort study.
Miyazaki T, Fukushima K, Hashiguchi K, Ide S, Kobayashi T, Sawai T, Yatera K, Kohno Y, Fukuda Y, Futsuki Y, Matsubara Y, Koga H, Mihara T, Sasaki E, Ashizawa N, Hirayama T, Takazono T, Yamamoto K, Imamura Y, Kaku N, Kosai K, Morinaga Y, Yanagihara K, Mukae H.
Pneumonia (Nathan). 2023 Oct 25;15(1):16. https://doi.org/10.1186/s41479-023-00118-4
12) Isoxanthohumol improves obesity and glucose metabolism via inhibiting intestinal lipid absorption with a bloom of Akkermansia muciniphila in mice.
Watanabe Y, Fujisaka S, Morinaga Y, Watanabe S, Nawaz A, Hatta H, Kado T, Nishimura A, Bilal M, Aslam M R, Honda K, Nakagawa Y, Softic S, Hirabayashi K, Nakagawa T, Nagai Y, Tobe K.
Mol Metab. 2023 Nov;77:101797. https://doi.org/10.1016/j.molmet.2023.101797
NEWS
2022
1) Kawamoto Y, Kaku N, Akamatsu N, Sakamoto K, Kosai K, Morinaga Y, Ohmagari N, Izumikawa K, Yamamoto Y, Mikamo H, Kaku M, Oishi K, Yanagihara K. The surveillance of colistin resistance and mobilized colistin resistance genes in multidrug-resistant Enterobacteriaceae isolated in Japan. Int J Antimicrob Agents. 2022 Jan; 59(1): 106480.
doi: 10.1016/ j.ijantimicag.2021.106480.
2) Nagaoka K, Kawasuji H, Murai Y, Kaneda M, Ueno A, Miyajima Y, Fukui Y, Morinaga Y, Yamamoto Y. Circulating type I interferon levels in the early phase of COVID-19 are associated with the development of respiratory failure. Front Immunol.2022 Feb 14; 13: 844304. doi: 10.3389/fimmu.2022.844304.
3) Kondo T, Sakamoto K, Morinaga Y, Miyata Y, Yanagihara K, Sakai H. Escherichia coli ST131 isolated from urologicalpatients can acquire plasmid-mediated extended spectrum β-lactamase from other bacteria with high frequency. Int j Urol.2022 Mar 14; 29(6): 587-594.
doi: 10.1111/iju.14845.
4) Ito Y, Takazono T, Obase Y, Fukahori S, Ashizawa N, Hirayama T, Tashiro M, Yamamoto K, Imamura Y, Hosogaya N,Fukushima C, Morinaga Y, Yanagihara K, Izumikawa K, Mukae H. Serum cytokines usefulness for understanding thepathology in allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis. J Fungi (Basel). 2022 Apr 23;8(5): 436.
doi: 10.3390/jof8050436.
5) Ozawa T, Tani H, Anraku Y, Kita S, Igarashi E, Saga Y, Inasaki N, Kawasuji H, Yamada H, Sasaki SI, Somekawa M, Sasaki J, Hayakawa Y, Yamamoto Y, Morinaga Y, Kurosawa N, Isobe M, Fukuhara H, Maenaka K, Hashiguchi T, Kishi H, Kitajima I, Saito S, Niimi H. Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. MAbs. 2022 May 11; 14(1): 2072455. doi: 10.1080/19420862.2022.2072455.
NEWS
チューリップテレビ「富大が発表 3回目接種『オミクロン株にも効果』」にてコメントが放映されました Morinaga Y / 2022 Jul 11.
ラジオ日経「呼吸器ウイルス感染症のこれから」
Morinaga Y / 2022 Jul 11
渡辺帆乃花さん（学部4回生）が第92回日本感染症学会西日本地方会学術集会・第65回日本感染症学会西日本地方会学術集会・第70回日本化学療法学会西日本支部総会にて優秀賞（口頭）を受賞しました / Watanabe H, 2022 Nov 4
渡辺帆乃花さん（学部4回生）が2022年度バイオインフォマティクス技術者認定試験に合格しました / Watanabe H, 2022 Dec 27
2021
1) Tani H, Kimura M, Tan L, Yoshida Y, Ozawa T, Kishi H, Fukushi S, Saijo M, Sano K, Suzuki T, Kawasuji H, Ueno A,Miyajima Y, Fukui Y, Sakamaki I, Yamamoto Y, Morinaga Y. Evaluation of SARS-CoV-2 neutralizing antibodies using avesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Virol J. 2021 Jan 12; 18(1): 16. doi:10.1186/s12985-021-01490-7.
2) Kuwatsuka S, Kuwatsuka Y, Tomimura S, Takenaka M, Terasaka Y, zumikawa K, Morinaga Y, Yanagihara K, Murota H. Impact of daily wearing of fabric gloves on the management of hand eczema: A pilot study in health-care workers. J Dermatol. 2021 May; 48(5): 645-50. doi: 10.1111/1346-8138.15848.
3) Taniguchi D, Watanabe H, Morinaga Y, Sasaki D, Matsuda J, Sato S, Kaku N, Miyazaki T, Matsumoto K, Tsuchiya T, Sakaeda T, Yanagihara K, Nagayasu T. Safety, efficacy, and analysis of key parameters after prophylactic administration of a sustained-release formulation of azithromycin in lung cancer surgery. Ann Palliat Med. 2021 May; 10(5): 5098-107. doi: 10.21037/apm-21-383.
4) Kaku N, Kodama H, Akamatsu N, Ota K, Kosai K, Morinaga Y, Narita Y, Matsumoto Y, Matsushita T, Mizuta Y, Izumikawa K, Mukae H, Yanagihara K. Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syncytial virus in patients with influenza-like illness. J Infect Chemother. 2021 Jun; 27(6): 820-5. doi: 10.1016/j.jiac.2021.01.010.
5) Yamada H, Taniguchi S, Shimojima M, Tan L, Kimura M, Morinaga Y, Fukuhara T, Matsuura Y, Komeno T, Furuta Y, Saijo M, Tani H. M Segment-Based Minigenome System of Severe Fever with Thrombocytopenia Syndrome Virus as a Tool for Antiviral Drug Screening. Viruses. 2021 Jun 3; 13(6): 1061. doi: 10.3390/v13061061.
NEWS
European Journal of Clinical Microbiology & Infectious Diseases誌に論文が掲載されることとなりました/Morinaga Y.2021.Feb.9
Journal of Infection and Chemotherapy誌に論文が掲載されることとなりました/Morinaga Y.2021.Jan.25
NHK富山放送局、ケーブルテレビ、北日本新聞、富山新聞「感染症医療人養成にむけた富山大学の教育への取り組み」コメント放映・掲載されました/Morinaga Y.2021,Nov.16
NHK富山放送局の番組で集団食中毒についてのコメントが放映されました/Morinaga Y.2021.Jun.19
Virology Journal誌に当大学感染症学講座と、富山県衛生研究所が中心となり、当大学免疫学、国立感染症研究所と共同で行った新型コロナウイルスに対する免疫力を示す中和抗体に関する論文が掲載されました/Morinaga Y.2021,Jan.12
2020
1) Tani H, Kimura M, Tan L, Yoshida Y, Ozawa T, Kishi H, Fukushi S, Saijo M, Sano K, Suzuki T, Kawasuji H, Ueno A,Miyajima Y, Fukui Y, Sakamaki I, Yamamoto Y, Morinaga Y. Evaluation of SARS-CoV-2 neutralizing antibodies using avesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Virol J. 2021 Jan 12; 18(1): 16. doi:10.1186/s12985-021-01490-7.
2) Kuwatsuka S, Kuwatsuka Y, Tomimura S, Takenaka M, Terasaka Y, zumikawa K, Morinaga Y, Yanagihara K, Murota H. Impact of daily wearing of fabric gloves on the management of hand eczema: A pilot study in health-care workers. J Dermatol. 2021 May; 48(5): 645-50. doi: 10.1111/1346-8138.15848.
3) Taniguchi D, Watanabe H, Morinaga Y, Sasaki D, Matsuda J, Sato S, Kaku N, Miyazaki T, Matsumoto K, Tsuchiya T, Sakaeda T, Yanagihara K, Nagayasu T. Safety, efficacy, and analysis of key parameters after prophylactic administration of a sustained-release formulation of azithromycin in lung cancer surgery. Ann Palliat Med. 2021 May; 10(5): 5098-107. doi: 10.21037/apm-21-383.
4) Kaku N, Kodama H, Akamatsu N, Ota K, Kosai K, Morinaga Y, Narita Y, Matsumoto Y, Matsushita T, Mizuta Y, Izumikawa K, Mukae H, Yanagihara K. Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syncytial virus in patients with influenza-like illness. J Infect Chemother. 2021 Jun; 27(6): 820-5. doi: 10.1016/j.jiac.2021.01.010.
5) Yamada H, Taniguchi S, Shimojima M, Tan L, Kimura M, Morinaga Y, Fukuhara T, Matsuura Y, Komeno T, Furuta Y, Saijo M, Tani H. M Segment-Based Minigenome System of Severe Fever with Thrombocytopenia Syndrome Virus as a Tool for Antiviral Drug Screening. Viruses. 2021 Jun 3; 13(6): 1061. doi: 10.3390/v13061061.
NEWS
Journal of Medical Microbiology誌に論文が掲載されました/Morinaga Y_2020,Nov.3
Infection and Chemotherapy誌に当大学感染症科と共同での論文が掲載されました/Morinaga Y,2020Aug.20
Interdisciplinary Neurosurgery誌に当大学脳神経外科と共同での論文が掲載されました/Morinaga Y,2020Jul.
教員4名が学長表彰を受けました/ Morinaga Y, Tani H, Yamada H, Kimura M, 2020,Apr.23
富山テレビ放送の番組「報道ライブBBT」でPCR検査についてのコメントが放映されました/Morinaga Y, 2020,Apr.21